PAP
ASND icon

Persistent Asset Partners’s Ascendis Pharma A/S ASND Stock Holding History

Persistent Asset Partners’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-237
Closed -$27.1K – 819
2026
Q1 		$27.1K Buy
+237
New +$53.1K 0.01% 273

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Persistent Asset Partners's ASND Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 327 shares worth $87.2K. The stake represents 0.03% of the portfolio and ranks #315 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in ASND as recently as Q4 2025.

Persistent Asset Partners first reported a position in ASND in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.26M in Q3 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Persistent Asset Partners held 327 shares of Ascendis Pharma A/S worth $87.2K as of Q2 2026.
  • Ascendis Pharma A/S was a new Persistent Asset Partners position in Q2 2026.
  • Ascendis Pharma A/S made up 0.03% of Persistent Asset Partners's portfolio in Q2 2026, its #315 holding.
  • Persistent Asset Partners first reported a position in Ascendis Pharma A/S in Q4 2024 and has held it in 5 quarters since.
  • Persistent Asset Partners's Ascendis Pharma A/S position peaked at $1.26M in Q3 2025.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.